Erbliche Anfälligkeit für akute myeloische Leukämie

Kode A et al. (2014) Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts.

Smith ML et al. (2004) Mutation of CEBPA in familial acute myeloid leukemia.

Matsunaga T et al. (2003) Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.

Hahn CN et al. (2011) Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Mardis ER et al. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome.

et al. (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Miller CA et al. (2013) Genomic landscapes and clonality of de novo AML.

Brewin J et al. (2013) Genomic landscapes and clonality of de novo AML.

Le Beau MM et al. (1993) Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.

Lee JW et al. (2006) The JAK2 V617F mutation in de novo acute myelogenous leukemias.

Shlush LI et al. (2014) Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.

Gelsi-Boyer V et al. (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Carbuccia N et al. (2009) Mutations of ASXL1 gene in myeloproliferative neoplasms.

Horwitz M et al. (1996) A family inheriting different subtypes of acute myelogenous leukemia.

Horwitz M et al. (1996) Anticipation in familial leukemia.

Bollag G et al. (1996) Biochemical characterization of a novel KRAS insertion mutation from a human leukemia.

Horwitz M et al. (1997) Genetic heterogeneity in familial acute myelogenous leukemia: evidence for a second locus at chromosome 16q21-23.2.

Shields JA et al. (2003) Bilateral orbital myeloid sarcoma as initial sign of acute myeloid leukemia: case report and review of the literature.

Falini B et al. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Grisendi S et al. (2005) NPM mutations in acute myelogenous leukemia.

Barjesteh van Waalwijk van Doorn-Khosrovani S et al. (2005) Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia.

Jin L et al. (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells.

Mullican SE et al. (2007) Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia.

Gale RE et al. (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Garzon R et al. (2008) Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.

Schlenk RF et al. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Calado RT et al. (2009) Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.

Delhommeau F et al. (2009) Mutation in TET2 in myeloid cancers.

Garzon R et al. (2009) MicroRNA 29b functions in acute myeloid leukemia.

Marcucci G et al. (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Harutyunyan A et al. (2011) p53 lesions in leukemic transformation.

Boissel N et al. (2011) Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Ding L et al. (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.

Smith CC et al. (2012) Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Venstrom JM et al. (2012) HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

Santos MA et al. (2014) DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier.

Wong TN et al. (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.

Illendula A et al. (2015) Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.

Fong CY et al. (2015) BET inhibitor resistance emerges from leukaemia stem cells.

Rathert P et al. (2015) Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.

Ivey A et al. (2016) Assessment of Minimal Residual Disease in Standard-Risk AML.

OMIM.ORG article